Robert Koch, DO
Cardiovascular Disease · Libertyville, ILNPI 1962497974
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $263,073 of the $297,893 with a category attached, or 88.3%. 52 manufacturers reported payments, led by Boehringer Ingelheim at 45.9% of the total. Reporting peaked in 2019 at $110,698 and has fallen 83.6% since, to $18,101 in 2025. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,271 payments — averaging $234.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$137K
- Amarin Pharma, Inc.$89K
- Lilly USA, LLC$40K
- AstraZeneca$18K
- Johnson & Johnson$2K
- E.r. Squibb & Sons, L.L.C.$2K
- plus $11K from 46 others
What the payments were for
- Consulting fees$3,3751%
- Speaking & faculty fees$263,07388%
- Travel & lodging$3,9781%
- Food & beverage$27,3399%
- Education$1290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$297,893 in reported general payments places this provider in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 504 | $720,441 |
| VyndamaxTafamidis | 19 | $700,044 |
| VascepaIcosapent Ethyl | 648 | $569,021 |
| EliquisApixaban | 300 | $379,232 |
| XareltoRivaroxaban | 61 | $83,018 |
| EntrestoSacubitril/Valsartan | 34 | $61,068 |
| Nebivolol Hcl | 713 | $42,336 |
| FarxigaDapagliflozin Propanediol | 23 | $34,457 |
| Perindopril Erbumine | 393 | $29,192 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 68 | $28,884 |
| CorlanorIvabradine Hcl | 14 | $21,535 |
| EdarbiAzilsartan Medoxomil | 37 | $21,005 |
| Telmisartan | 649 | $20,167 |
| Ranolazine ErRanolazine | 154 | $17,647 |
| Repatha SureclickEvolocumab | 30 | $17,305 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $1,390 | $1,079,276319 claims |
| Boehringer IngelheimJardiance, Pradaxa | $136,748 | $728,770524 claims |
| Johnson & JohnsonXarelto | $1,928 | $83,01861 claims |
| NovartisEntresto | $1,347 | $61,06834 claims |
| AstraZenecaFarxiga | $17,788 | $34,45723 claims |
| AmgenCorlanor | $1,274 | $21,53514 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $43 | $21,00537 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Libertyville
- Sandeep NathanChicago$892K
- Alan BrownNaperville$858K
- Azmey MatariehElgin$762K
- Jay AlexanderBannockburn$744K
- Niraj VarmaMaywood$522K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Mark RabbatMaywood$363K
- Michael DavidsonChicago$317K
- Jyothy PuthumanaChicago$269K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.